Stable Gastric Pentadecapeptide BPC 157 as a Therapy of Severe Electrolyte Disturbances in Rats.
This review paper examines the potential therapeutic role of BPC 157 (a synthetic 15-amino-acid peptide derived from a gastric protein) in treating severe electrolyte disturbances, drawing on a collection of animal and in-vitro experiments. The paper covers four electrolyte scenarios: (1) hyperkalemia — where BPC 157 was reported to counteract KCl overdose effects including arrhythmias, hypertension, sphincter dysfunction, and mortality in rat models; (2) hypokalemia — where BPC 157 administration (both prophylactically and therapeutically) was reported to prevent fatal outcomes, ECG abnormalities, AV block, and skeletal muscle myoclonus in furosemide-treated rats; (3) hypermagnesemia — where BPC 157 appeared to alleviate muscle weakness, brain lesions, and secondary hyperkalemia in rats; and (4) lithium intoxication — where BPC 157 was reported to promote collateral vascular pathways and resolve multiorgan failure features. In-vitro experiments using HEK293 cells suggested BPC 157 can modulate membrane potential changes induced by electrolyte imbalances. Key limitations include reliance on animal and cell-based data with no human clinical trials reported, and the review format limits independent assessment of individual study methodologies.
Why this grade: This is a review of preclinical studies conducted exclusively in rat models and HEK293 cell lines, with no human clinical trial data presented, limiting evidence applicability to humans.
This review explores the therapeutic potential of the stable gastric pentadecapeptide BPC 157 in addressing electrolyte imbalances, specifically hyperkalemia, hypokalemia, hypermagnesemia, and hyperlithiemia. In hyperkalemia, BPC 157 demonstrated a comprehensive counteractive effect against KCl overdose (intraperitoneally, intragastrically, and in vitro), effectively mitigating symptoms such as muscular weakness, hypertension, sphincter dysfunction, arrhythmias, and lethality. It also counteracted the adverse effects of succinylcholine and magnesium overdose, including systemic muscle paralysis, arrhythmias, and hyperkalemia. In hypokalemia, BPC 157 (administered prophylactically or therapeutically, intraperitoneally or intragastrically) prevented fatal outcomes and addressed furosemide-induced hypokalemia, ECG changes, AV conduction block, ventricular arrhythmias, and skeletal muscle myoclonus. Following magnesium overdose, BPC 157 alleviated muscle weakness, brain lesions, and hyperkalemiainduced complications. In vitro studies (HEK293 cells) revealed the ability of BPC 157 to counteract hyperkalemia- and hypermagnesemia-induced depolarization and hypokalemia-induced hyperpolarization. In lithium intoxication, BPC 157 promoted collateral pathway activation, resolved vascular and multiorgan failure, and counteracted advanced Virchow triad conditions and occlusion-like syndromes. Collectively, these findings underscore the therapeutic promise of BPC 157 in managing electrolyte imbalances and warrant further investigation.
Educational summary of published research — not medical advice. Full text is shown only where licensing permits.